A comparison of the efficiency of rosuvastatin, atorvastatin and simvastatin in achieving target lipid levels

Oleg V. Gaisenok

The need to use statins to achieve the target levels of total cholesterol (TC), LDL-C, HDL-C and triglycerides (TG) is emphasized in international recommendations [1]. The relationship between the level of LDL and the frequency of cardiovascular complications has been proved in large studies [2-7]. Despite the existing recommendations, Russian realities have always differed from the situation in Western Europe and the United States. Thus, the following results were obtained in the Moscow statins study: only 30% of patients with IHD received statins; 80% of the appointments were simvastatin and lovastatin in the initial doses; the average duration of treatment was 5 months [8]. The first generation of statins (pravastatin, lovastatin) gave way to subsequent generations. Currently, in clinical practice, it is almost impossible to meet patients who take them. The most prescribed are well-proven simvastatin, atorvastatin and rosuvastatin. The role of the latter one in influencing the regression of atherosclerosis, cardiovascular and general mortality was devoted to large-scale international studies [9-12]. However, it should be noted that most studies of rosuvastatin were devoted to primary prevention of cardiovascular diseases; at the same time as atorvastatin has the greatest evidence base for secondary prevention [9,13-16].

© J Clin Med Kaz 2017; 3(45) doi:10.23950/1812-2892-JCMK

17 апреля 2018 года

Гайсёнок Олег Владимирович
Заведующий отделением общая кардиология

Гайсёнок Олег Владимирович

кандидат медицинских наук, врач-кардиолог высшей категории (GCP), член Российского и Европейского общества кардиологов (РКО, ESC), Национального общества по изучению атеросклероза (НОА), Национального общества доказательной фармакотерапии, член экспертного совета «Клуба аритмологов России».

Общая кардиология

Публикации по кардиологии